SCHEMBL8852297

SCHEMBL8852297

CCNCC(=O)OC(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.45
TSHR P16473 2/20 0.39
PPARG P37231 1/20 0.38
NCOA2 Q15596 1/20 0.38
NCOA1 Q15788 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
NLRP3 Q96P20 1/20 0.36
MAPT P10636 3/20 0.34
CYP2D6 P10635 1/20 0.33
BTN3A1 O00481 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.32
MMP3 P08254 1/20 0.32
MMP9 P14780 1/20 0.32
MMP13 P45452 1/20 0.32
MGAM O43451 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5933090 0.88 LMNA (0.45) LMNATSHRPPARGNCOA2NCOA1
SCHEMBL19174262 0.80 PPARG (0.41) LMNATSHRPPARGNCOA2NCOA1
SCHEMBL11191815 0.80 TSHR (0.41) LMNATSHRPPARGNCOA2NCOA1
SCHEMBL11800309 0.80 LMNA (0.39) LMNATSHRPPARGNCOA2NCOA1
SCHEMBL423404 0.79 LMNA (0.42) LMNATSHRPPARGNCOA2NCOA1
SCHEMBL10142215 0.78 LMNA (0.42) LMNATSHRPPARGNCOA2NCOA1
SCHEMBL18520800 0.78 LMNA (0.52) LMNATSHRMAPTALDH1A1HTT
Hydrochloric Acid SCHEMBL21629430 0.77 LMNA (0.41) LMNATSHRPPARGNCOA2NCOA1
SCHEMBL11236350 0.77 LMNA (0.41) LMNATSHRPPARGNCOA2NCOA1
SCHEMBL807477 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216513-A1 FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE NOVARTIS AG (CH) 2024-07-04 US disclosed
US-5618814-A Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds DR. KARL THOMAE GMBH (DE) 1997-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216513-A1 FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE FASN, FABP1, SCD LMNA 2491/4885TSHR 2284/4885PPARG 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.